Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Monogram Orthopaedics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SECOND QUARTER NET SALES OF $2.077 BILLION INCREASED 7.0% ON A REPORTED BASIS, 5.4% ON A CONSTANT CURRENCY1 BASIS AND 2.8% ON AN ORGANIC CONSTANT CURRENCY1 BASIS SECOND QUARTER DILUTED EARNINGS PER SHARE WERE $0.77; ADJUSTED1 DILUTED EARNINGS PER SHARE WERE $2.07, AN INCREASE OF 3.0% COMPANY TIGHTENS FULL-YEAR 2025 REPORTED, CONSTANT CURRENCY1 AND ORGANIC CONSTANT CURRENCY1 REVENUE GROWTH GUIDANCE TO 6.7% - 7.7%, 6.2% - 7.2% AND 3.5% - 4.5%, RESPECTIVELY, AND INCREASES ADJUSTED1 EARNINGS PER SHARE FINANCIAL GUIDANCE TO $8.10 - $8.30 WARSAW, IND. , AUG. 7, 2025 /PRNEWSWIRE/ -- ZIMMER BIOMET HOLDINGS, INC. (NYSE AND SIX: ZBH) TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2025.

ZIMMER BIOMET ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS

THE PROCEDURE UTILIZED MONOGRAM'S MBS TKA SYSTEM PERFORMED IN INDIA WITH SHALBY HOSPITALS GROUNDBREAKING PROCEDURE DELIVERS THE WORLD'S FIRST AUTONOMOUS SAW-BASED ROBOTIC TKA SURGERY ON A LIVE PATIENT AUSTIN, TEXAS, JULY 29, 2025 (GLOBE NEWSWIRE) -- MONOGRAM TECHNOLOGIES INC. (NASDAQ: MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY REVOLUTIONIZING ORTHOPEDIC SURGERY, TODAY ANNOUNCED THAT ON SATURDAY, JULY 26, 2025, MONOGRAM COMPLETED THE FIRST EVER FULLY AUTONOMOUS SAW-BASED ROBOTIC KNEE REPLACEMENT PROCEDURE ON A LIVE PATIENT. THE PROCEDURE WAS PERFORMED AT THE KRISHNA SHALBY HOSPITAL IN AHMEDABAD INDIA, AS PART OF MONOGRAM'S MULTI-CENTER CLINICAL TRIAL IN INDIA FOR THE MONOGRAM TKA SYSTEM.

MONOGRAM TECHNOLOGIES ANNOUNCES WORLD'S FIRST FULLY AUTONOMOUS SAW-BASED ROBOTIC KNEE REPLACEMENT SURGERY

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF MONOGRAM TECHNOLOGIES INC. (NASDAQCM: MGRM) TO ZIMMER BIOMET HOLDINGS, INC. (NYSE: ZBH). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF MONOGRAM WILL RECEIVE AN UPFRONT PAYMENT OF $4.04 PER SHARE IN CASH, AND A NON-TRADEABLE CONTINGENT VALUE RIGHT ENTITLING THE HOLDER TO RECEIVE U.

MONOGRAM TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF MONOGRAM TECHNOLOGIES INC. - MGRM

PROPOSED TRANSACTION CREATES THE BROADEST, MOST FLEXIBLE PORTFOLIO OF ORTHOPEDIC ROBOTICS AND NAVIGATION TECHNOLOGIES TO MEET SURGEONS' NEEDS ACQUISITION EXPECTED TO BE NEUTRAL TO ADJUSTED EARNINGS PER SHARE IN 2025  2027 AND ACCRETIVE THEREAFTER AND TO CONTRIBUTE TO REVENUE GROWTH BEGINNING IN 2027 WARSAW, INDIANA AND AUSTIN, TEXAS, JULY 14, 2025 (GLOBE NEWSWIRE) -- ZIMMER BIOMET HOLDINGS, INC. (NYSE AND SIX: ZBH), A GLOBAL MEDICAL TECHNOLOGY LEADER, AND MONOGRAM TECHNOLOGIES INC. (NASDAQ: MGRM), AN ORTHOPEDIC ROBOTICS COMPANY, TODAY ANNOUNCED THEY HAVE ENTERED INTO A DEFINITIVE AGREEMENT FOR ZIMMER BIOMET TO ACQUIRE ALL OUTSTANDING SHARES OF STOCK OF MONOGRAM FOR AN UPFRONT PAYMENT OF $4.04 PER SHARE IN CASH, CORRESPONDING TO AN EQUITY VALUE OF APPROXIMATELY $177 MILLION AND AN ENTERPRISE VALUE OF APPROXIMATELY $168 MILLION. MONOGRAM COMMON STOCKHOLDERS WILL ALSO RECEIVE A NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) ENTITLING THE HOLDER TO RECEIVE UP TO $12.37 PER SHARE OF COMMON STOCK IN CASH IF CERTAIN PRODUCT DEVELOPMENT, REGULATORY AND REVENUE MILESTONES ARE ACHIEVED THROUGH 2030.

ZIMMER BIOMET ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE MONOGRAM TECHNOLOGIES, EXPANDING ROBOTICS SUITE WITH AUTONOMOUS SOLUTIONS

PROPOSED TRANSACTION CREATES THE BROADEST, MOST FLEXIBLE PORTFOLIO OF ORTHOPEDIC ROBOTICS AND NAVIGATION TECHNOLOGIES TO MEET SURGEONS' NEEDS ACQUISITION EXPECTED TO BE NEUTRAL TO ADJUSTED EARNINGS PER SHARE IN 2025  2027 AND ACCRETIVE THEREAFTER AND TO CONTRIBUTE TO REVENUE GROWTH BEGINNING IN 2027 WARSAW, IND. AND AUSTIN, TEXAS , JULY 14, 2025 /PRNEWSWIRE/ -- ZIMMER BIOMET HOLDINGS, INC. (NYSE AND SIX: ZBH), A GLOBAL MEDICAL TECHNOLOGY LEADER, AND MONOGRAM TECHNOLOGIES INC. (NASDAQ: MGRM), AN ORTHOPEDIC ROBOTICS COMPANY, TODAY ANNOUNCED THEY HAVE ENTERED INTO A DEFINITIVE AGREEMENT FOR ZIMMER BIOMET TO ACQUIRE ALL OUTSTANDING SHARES OF STOCK OF MONOGRAM FOR AN UPFRONT PAYMENT OF $4.04 PER SHARE IN CASH, CORRESPONDING TO AN EQUITY VALUE OF APPROXIMATELY $177 MILLION AND AN ENTERPRISE VALUE OF APPROXIMATELY $168 MILLION.

AUSTIN, TEXAS / ACCESS NEWSWIRE / JULY 8, 2025 / MONOGRAM TECHNOLOGIES INC. (NASDAQ:MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY REVOLUTIONIZING ORTHOPEDIC SURGERY, TODAY ANNOUNCED THE MANDATORY CONVERSION OF ALL OUTSTANDING SHARES OF 8.00% SERIES D CONVERTIBLE CUMULATIVE PREFERRED STOCK (THE "SERIES D PREFERRED STOCK") THAT WERE ISSUED IN CONNECTION WITH THE COMPANY'S OFFERING THAT CLOSED ON OCTOBER 1, 2024 (THE "OFFERING"). DURING THE OFFERING, THE COMPANY ISSUED AND SOLD UNITS, WITH EACH UNIT CONSISTING OF (A) ONE SHARE OF THE COMPANY'S SERIES D PREFERRED STOCK AND (B) ONE COMMON STOCK PURCHASE WARRANT TO PURCHASE ONE SHARE OF THE COMPANY'S COMMON STOCK, $0.001 PAR VALUE PER SHARE (THE "COMMON STOCK").

MONOGRAM TECHNOLOGIES ANNOUNCES THE MANDATORY CONVERSION OF 8.00% SERIES D CONVERTIBLE CUMULATIVE PREFERRED STOCK

RECEIVES FDA CLEARANCE FOR THE MBS TKA SYSTEM GROUNDBREAKING TRIAL SET TO DELIVER ONE OF THE WORLD'S FIRST AUTONOMOUS SAW-BASED ROBOTIC TKA SURGERIES ON LIVE PATIENTS MANAGEMENT TO HOST BUSINESS UPDATE CONFERENCE CALL TODAY AT 4:30 P.M. EASTERN TIME AUSTIN, TEXAS, MAY 14, 2025 (GLOBE NEWSWIRE) -- MONOGRAM TECHNOLOGIES INC. (NASDAQ: MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY FOCUSED ON IMPROVING HUMAN HEALTH WITH AN INITIAL FOCUS ON ORTHOPEDIC SURGERY, HAS REPORTED ITS FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

MONOGRAM TECHNOLOGIES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

AUSTIN, TX / ACCESS NEWSWIRE / MAY 6, 2025 / MONOGRAM TECHNOLOGIES INC. (NASDAQ:MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY REVOLUTIONIZING ORTHOPEDIC SURGERY, WILL HOLD A CONFERENCE CALL WEBCAST ON WEDNESDAY, MAY 14, 2025 AT 4:30 P.M. EASTERN TIME IN CONJUNCTION WITH ITS REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND TO DISCUSS REGULATORY UPDATES, INCLUDING ITS RECENT FDA 510(K) CLEARANCE FOR THE MONOGRAM MBSTM TKA SYSTEM AND APPROVAL TO START CLINICAL TRIALS IN INDIA, AND KEY MILESTONES.

MONOGRAM TECHNOLOGIES TO HOST FIRST QUARTER 2025 RESULTS CONFERENCE CALL ON WEDNESDAY, MAY 14, 2025 AT 4:30 P.M. EASTERN TIME

MONOGRAM GRANTED REGULATORY APPROVAL TO IMPORT MBS TKA SYSTEM FOR CLINICAL INVESTIGATION PATIENT ENROLLMENT WILL BEGIN SHORTLY; FIRST LIVE PATIENT SURGERIES ARE ANTICIPATED WITHIN 90 BUSINESS DAYS CRITICAL MILESTONE ACHIEVED FOR MULTI-CENTER CLINICAL TRIAL IN INDIA WITH STRATEGIC PARTNER SHALBY HOSPITALS FOR THE MBS TKA SYSTEM AUSTIN, TX / ACCESS NEWSWIRE / APRIL 29, 2025 / MONOGRAM TECHNOLOGIES INC. (NASDAQ:MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY REVOLUTIONIZING ORTHOPEDIC SURGERY, TODAY ANNOUNCED IT HAS OBTAINED REGULATORY APPROVAL FROM INDIA'S CENTRAL DRUGS STANDARD CONTROL ORGANIZATION ("CDSCO") TO IMPORT ITS MBS TKA SYSTEM TO CONDUCT A 102-PATIENT, MULTI-CENTER CLINICAL INVESTIGATION EVALUATING THE SAFETY AND EFFECTIVENESS OF THE MONOGRAM TKA SYSTEM. THE STUDY WILL BE CONDUCTED IN COLLABORATION WITH SHALBY LIMITED (NSE: SHALBY) ("SHALBY"), ONE OF THE WORLD'S LARGEST ORTHOPEDIC HOSPITAL GROUPS.

CORRECTION FROM SOURCE: MONOGRAM TECHNOLOGIES RECEIVES REGULATORY APPROVAL TO START CLINICAL TRIALS IN INDIA

AUSTIN, TX / ACCESS NEWSWIRE / MARCH 20, 2025 / MONOGRAM TECHNOLOGIES INC. (NASDAQ:MGRM) ("MONOGRAM" OR THE "COMPANY"), AN AI-DRIVEN ROBOTICS COMPANY FOCUSED ON IMPROVING HUMAN HEALTH WITH AN INITIAL FOCUS ON ORTHOPEDIC SURGERY, IS PLEASED TO ANNOUNCE ITS PARTNERSHIP WITH URVIN, A PRIVATE, VERIFIED MESSAGE BOARD EXCLUSIVELY FOR ACTIVE MONOGRAM SHAREHOLDERS. THIS PLATFORM OFFERS A WAY FOR SHAREHOLDERS TO COMMUNICATE DIRECTLY WITH EACH OTHER WHILE PROVIDING MONOGRAM WITH AN ADDITIONAL TOOL TO PROVIDE IMPORTANT COMPANY UPDATES AND REACH THE BROADEST POSSIBLE SHAREHOLDER AUDIENCE.

Monogram Orthopaedics, Inc.

MGRM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Monogram Orthopaedics, Inc.

MGRM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MGRM